Skip to main content

Introduction to CSL Behring study for Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Two Dose Levels of Privigen in Pediatric CIDP
NCT03684018 | Phase 4 | Interventional

A randomized, open-label, prospective, multicenter study designed to investigate 2 dose levels in pediatric subjects 2 to ≤ 17 years of age with confirmed or possible CIDP, either previously exposed to IVIG treatment or unexposed to IVIG treatment

Trial Information
6 Sites
30 Participants
2 Years to 17 Years

If interested, contact for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Children's Hospital of Los Angeles
Los Angeles,California,United States,90027
University of Iowa Hospitals and Clinics
Iowa City,Iowa,United States,52242-1009
Akron Children's Hospital
Akron,Ohio,United States,44647
Children's Hospital of Philadelphia
Philadelphia,Pennsylvania,United States,19104
Neurology Rare Disease Center
Denton,Texas,United States,76208
Children's Specialty Group
Norfolk,Virginia,United States,23507

Study Eligibility Criteria

  • Male or female subjects 2 to ≤ 17 years of age with confirmed or possible CIDP.
  • Absence of CIDP symptoms
  • History or family history of inherited neuropathy
  • Diagnosed developmental delay or regression
  • History of thrombotic episode
  • Known or suspected hypersensitivity to Privigen
  • Known allergic or other severe reactions to blood products
  • Female subject of childbearing potential either not using or not willing to use a medically reliable method of contraception or not sexually abstinent during the study
  • Pregnant or breastfeeding mother"

Additional Studies

Additional studies can be found at